Novo Nordisk A/S Company Profile (NYSE:NVO)

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S logoNovo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:NVO
  • CUSIP: N/A
  • Web:
  • Market Cap: $121.8 billion
  • Outstanding Shares: 2,480,199,000
Average Prices:
  • 50 Day Moving Avg: $45.97
  • 200 Day Moving Avg: $41.13
  • 52 Week Range: $30.89 - $49.26
  • Trailing P/E Ratio: 19.66
  • Foreward P/E Ratio: 18.74
  • P/E Growth: 2.38
Sales & Book Value:
  • Annual Revenue: $18.36 billion
  • Price / Sales: 6.63
  • Book Value: $3.14 per share
  • Price / Book: 15.64
  • Annual Dividend: $0.82
  • Dividend Yield: 2.0%
  • EBIDTA: $8.65 billion
  • Net Margins: 33.82%
  • Return on Equity: 87.49%
  • Return on Assets: 40.72%
  • Current Ratio: 1.35%
  • Quick Ratio: 1.00%
  • Average Volume: 1.67 million shs.
  • Beta: 0.6
  • Short Ratio: 2.38

Frequently Asked Questions for Novo Nordisk A/S (NYSE:NVO)

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced an annual dividend on Wednesday, August 9th. Stockholders of record on Monday, August 21st will be given a dividend of $0.336 per share on Tuesday, August 29th. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend is Friday, August 18th. This is a positive change from Novo Nordisk A/S's previous annual dividend of $0.33. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its board has approved a share buyback program on Thursday, April 6th 2017, which authorizes the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 18.9% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board believes its stock is undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Friday, April, 29th. The company reported $0.55 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.53 by $0.02. The firm had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $4.07 billion. Novo Nordisk A/S had a net margin of 33.82% and a return on equity of 87.49%. View Novo Nordisk A/S's Earnings History.

When will Novo Nordisk A/S make its next earnings announcement?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:

  • Goran A. Ando M.D., Chairman of the Board
  • Lars Fruergaard Joergensen, President, Chief Executive Officer
  • Jeppe Christiansen, Vice Chairman of the Board
  • Jesper Brandgaard, Chief Financial Officer, Executive Vice President
  • Maziar Mike Doustdar, Executive Vice President, International Operations
  • Mads Krogsgaard Thomsen, Chief Science Officer, Executive Vice President
  • Doug Langa, Executive Vice President, North America Operations
  • Henrik Ehlers Wulff, Executive Vice President, Product Supply
  • Liselotte Hyveled, Director, Employee Representative
  • Kasim Kutay, Director

Who owns Novo Nordisk A/S stock?

Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.69%), Fisher Asset Management LLC (0.60%), Folketrygdfondet (0.35%), State Street Corp (0.22%), FMR LLC (0.28%) and Fayez Sarofim & Co. (0.26%). View Institutional Ownership Trends for Novo Nordisk A/S.

Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sustainable Growth Advisers LP, First Trust Advisors LP, Ameriprise Financial Inc., JPMorgan Chase & Co., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Fayez Sarofim & Co. and Dividend Assets Capital LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Folketrygdfondet, River Road Asset Management LLC, Nationwide Fund Advisors, Janus Henderson Group PLC, Guardian Capital LP, Tekla Capital Management LLC and Capital Fund Management S.A.. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy Novo Nordisk A/S stock?

Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of Novo Nordisk A/S stock can currently be purchased for approximately $49.11.

MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novo Nordisk A/S (NYSE:NVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Hold Ratings
Consensus Rating:Hold (Score: 1.67)
Consensus Price Target: N/A

Analysts' Ratings History for Novo Nordisk A/S (NYSE:NVO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Bank of America CorporationUpgradeUnderperform -> NeutralLowView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
1/3/2017J P Morgan Chase & CoDowngradeNeutral -> UnderweightN/AView Rating Details
12/20/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
12/1/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
10/31/2016DNB MarketsDowngradeBuy -> HoldN/AView Rating Details
10/31/2016Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/13/2016BNP ParibasUpgradeNeutral -> OutperformN/AView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformN/AView Rating Details
9/12/2016Deutsche Bank AGUpgradeHold -> BuyN/AView Rating Details
9/1/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
6/28/2016Goldman Sachs Group, Inc. (The)DowngradeConviction-Buy -> BuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyN/AView Rating Details
9/21/2015SwedbankUpgradeStrong-BuyN/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Novo Nordisk A/S (NYSE:NVO)
Earnings by Quarter for Novo Nordisk A/S (NYSE:NVO)
Earnings History by Quarter for Novo Nordisk A/S (NYSE NVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/29/2016Q1$0.53$0.55$4.07 billion$4.02 billionViewListenView Earnings Details
10/29/2015Q3$0.47$0.49$4.03 billion$3.99 billionViewN/AView Earnings Details
4/30/2015Q1$0.39$0.45$25.13 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details
5/1/2014Q1$0.44$0.45$20.83 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42ViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
2017 EPS Consensus Estimate: $2.15
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.52$0.52$0.52
Q2 20172$0.52$0.60$0.56
Q3 20171$0.55$0.55$0.55
Q4 20171$0.52$0.52$0.52
(Data provided by Zacks Investment Research)


Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)
Most Recent Dividend:8/29/2017
Annual Dividend:$0.82
Dividend Yield:1.67%
Dividend Growth:31.50% (3 Year Average)
Payout Ratio:36.44% (Trailing 12 Months of Earnings)
33.33% (Based on This Year's Estimates)
31.30% (Based on Next Year's Estimates)
Track Record:20 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Novo Nordisk A/S (NYSE:NVO)

Dividend History by Quarter for Novo Nordisk A/S (NYSE NVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership Percentage: 6.01%
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98
(Data available from 1/1/2013 forward)


Headline Trends for Novo Nordisk A/S (NYSE:NVO)
Latest Headlines for Novo Nordisk A/S (NYSE:NVO)
DateHeadline logoNovo Nordisk A/S (NVO) Given Average Recommendation of "Hold" by Brokerages - September 20 at 11:06 AM logoNovo Nordisk A/S (NVO) Upgraded by Zacks Investment Research to Buy - September 19 at 7:02 PM logoNovo Nordisk A/S : NVO-US: Dividend Analysis : August 21st, 2017 (record date) : By the numbers : September 18, 2017 - September 19 at 5:53 AM logoNovo Nordisk A/S (NVO) Downgraded by Zacks Investment Research to "Hold" - September 18 at 2:38 PM logoWells Fargo Commercial Mortgage Trust 2016-NXS6 -- Moody's Affirms Seven Classes of WFCM 2016-NXS6 - September 16 at 7:15 AM logoNovo Nordisk A/S (NVO) Upgraded to Buy at Zacks Investment Research - September 13 at 11:42 AM logoWith New CEO In Place, Focus For Teva Pharma Turns To 'Execution' - Benzinga - September 13 at 7:19 AM logoNovo Nordisk A/S (NVO) Rating Increased to Neutral at Bank of America Corporation - September 10 at 8:16 PM logoHere's Why Novo Nordisk A/S Gained 12% in August - The Motley Fool - Motley Fool - September 7 at 7:05 AM logoHere's Why Novo Nordisk A/S Gained 12% in August - September 7 at 7:05 AM logoHere's Why Novo Nordisk A/S Gained 12% in August - September 6 at 10:40 AM logoNovo Nordisk Settles U.S. Suit Over Victoza for $58.65 Million - September 6 at 6:59 AM logoNovo Nordisk announces conclusion of U.S. federal investigation of marketing practices - September 6 at 6:59 AM logoNovo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 mln - September 6 at 6:59 AM logoDanish drugmaker reaches settlement with US authorities - September 6 at 6:59 AM logoNovo Nordisk A/S (NVO) & Horizon Pharma PLC (HZNP) Critical Review - September 5 at 12:30 AM logoCorporate News Blog - Novo Nordisk’s Victoza(R) Receives Approval from FDA - August 30 at 7:23 AM logoNovo Nordisk's Tresiba Gets Canadian Nod - August 30 at 7:23 AM logoHealth Canada Approves Tresiba®, a New Basal Insulin for Type 1 and 2 Diabetes - August 29 at 6:10 AM logoETFs with exposure to Novo Nordisk A/S : August 28, 2017 - August 29 at 6:10 AM logoNovo Nordisk Diabetes Drug Victoza Approved In US To Reduce Cardiovascular Risk - Nasdaq - August 28 at 1:12 AM logoNovo Nordisk Diabetes Drug Victoza Approved In US To Reduce Cardiovascular Risk - August 27 at 8:11 PM logoNovo Nordisk A/S (NVO) Receives Average Recommendation of "Hold" from Brokerages - August 26 at 10:42 AM logoVictoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events - August 26 at 7:50 AM logoNovo Nordisk A/S (NVO) & BioLife Solutions (BLFS) Critical Comparison - August 24 at 1:18 PM logoNovo Nordisk A/S :NVO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017 - August 22 at 1:06 AM logoNovo Nordisk's diabetes drug succeeds in key trial (Aug 16) - August 17 at 4:56 PM logoNovo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for August 17, 2017 - Nasdaq - August 17 at 6:22 AM logo[$$] The New Innovator’s Dilemma: When Customers Won’t Pay for Better - August 16 at 2:43 AM logoEx-Dividend Reminder: Fortis, Atmos Energy and Novo-Nordisk - Nasdaq - August 15 at 4:34 PM logo[$$] When 'New and Improved' Fails: Insulin Maker Stumbles When Customers Balk - August 15 at 4:34 PM logoNovo Nordisk A/S Continues Its Comeback - August 14 at 4:29 PM logoLeerink Swann Comments on Novo Nordisk A/S's Q3 2017 Earnings (NYSE:NVO) - August 14 at 2:30 AM logoNovo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss - Nasdaq - August 13 at 12:41 AM logoNovo Nordisk A/S (NVO) Upgraded to "Hold" by BidaskClub - August 12 at 10:34 AM logoNovo Nordisk A/S to Post FY2017 Earnings of $2.38 Per Share, Leerink Swann Forecasts (NYSE:NVO) - August 11 at 10:45 AM logo Brokerages Expect Novo Nordisk A/S (NVO) Will Announce Quarterly Sales of $4.29 Billion - August 11 at 10:02 AM logoThe CEO of the world’s largest diabetes drugmaker says insulin pricing will change — it will just be slower than expected - August 11 at 7:07 AM logoNovo Nordisk A/S (NVO) Announces Dividend Increase - $0.34 Per Share - August 10 at 2:20 PM logo[$$] Novo Nordisk Upbeat on Sales Outlook Despite Flat Earnings - August 10 at 6:21 AM logo Brokerages Anticipate Novo Nordisk A/S (NYSE:NVO) to Announce $0.56 Earnings Per Share - August 9 at 8:24 PM logoComparing Novo Nordisk A/S (NVO) & Taro Pharmaceutical Industries (TARO) - August 9 at 8:40 AM logoNovo Nordisk H1 Profit Rises; Raises FY Operating Profit Growth Outlook - August 9 at 5:41 AM logoWhy Earnings Season Could Be Great for Novo Nordisk (NVO) - August 9 at 5:41 AM logoNovo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade - August 9 at 5:41 AM logoNovo Nordisk A/S (NYSE:NVO) to Release Quarterly Earnings on Wednesday - August 2 at 7:36 AM logoNovo Nordisk A/S (NVO) Receives Consensus Rating of "Hold" from Analysts - August 1 at 10:54 AM logoNovo Nordisk Says European Commission Approves Update To Victoza Label - Nasdaq - July 28 at 6:21 AM logoNovo Nordisk A/S (NYSE:NVO) Rating Lowered to Hold at Zacks Investment Research - July 24 at 12:20 PM logoContrasting Aegerion Pharmaceuticals (AEGR) & Novo Nordisk A/S (NYSE:NVO) - July 23 at 4:21 PM



Novo Nordisk A/S (NVO) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff